A2M (ASX) FDA Approval

Originally posted by Investau: ↑

I know there's been a lot of speculation about A2M Management asleep at the wheel, too busy lunching etc and I know it's crazy but lets just imagine for a moment they are acting in the best interests of advancing the company and growing revenue opportunities (crazy I know but hear me out):

I've been looking further into US consumption and purchasing of infant formula and, in particular, the WIC (Women, Infants, Children) programme. Firstly, a few stats I've been able to find as well as some educated assumptions:

- According to the USDA Economic Research Service, 60-70% of all infant formula purchased in the US is purchased through WIC.
- Through fiercely competitive bidding and exclusive rights grants, WIC buys from manufacturers at steeply discounted prices
- WIC claims $1.5-2Bn of savings and spends around $1Bn on formula implying an average discount from manufacturers of around 60-65%
- In Australia, a $35 tin of formula sold at a 25% margin assumes a fully loaded (incl. transport, marketing, wages, rent etc) cost per tin of $30
- If WIC is purchasing at 65% discount to retail this equates to around $10-12 per tin.
- Every tin sold to WIC invites a loss of $18-$20

We can speculate on US Govt funded shipping etc but that won't really impact the reality above and it's more likely than not that the long held monopolies in the US will resume their power after November.

Bubs has jumped on the opportunity to provide formula to the US and all praise to them. There is little doubt they are losing a fair bit of money by doing so but they are essentially investing in marketing to raise their brand profile and that works for them. They may get some advantage from selling outside of WIC in the longer term but I'd put a low percentage chance on that.

A2 Milk is in a very different position to Bubs and I would rather they focus on driving revenue and increasing margin in the most appropriate long term channels. I'm not saying they shouldn't entertain selling formula in the US but only if the deal is right and it's a long term play.

Finally, a lot of people are saying management should communicate more - I'd personally love to hear more from them but for what benefit? So I can profit from short term trading and speculation? That's not their role, they are there to drive long term growth in the business and they have clearly stated when they'll provide updates. Any commentary outside of that just invites complaints from those who feel they were misled.

We will no doubt see ups and downs over the remainder of the year and beyond but I have a lot of faith (and investment) in the long term growth of this company. The fundamentals impress me and there are some good contributions on these threads with real data, charts and commentary, everything else is just distracting noise.

GLTAH

Expand

Long term growth from its current levels for sure but I reckon the company's glory days of $20 type levels are over, newbs and those that bought below current price might still be excited, the larger majority will be thinking "Yeah Right".

No.	Vol.	Price($)
1	2420	$6.76

No.

Vol.

Price($)

2420

$6.76

Price($)	Vol.	No.
$6.77	37726	4

Price($)

Vol.

No.

$6.77

37726

No.	Vol.	Price($)
1	1000	6.740
2	700	6.700
1	5009	6.680
1	12000	6.650
1	1130	6.640

No.

Vol.

Price($)

1000

6.740

700

6.700

5009

6.680

12000

6.650

1130

6.640

Price($)	Vol.	No.
6.770	18339	2
6.780	500	1
6.790	3000	2
6.800	6054	6
6.810	600	1

Price($)

Vol.

No.

6.770

18339

6.780

500

6.790

3000

6.800

6054

6.810

600

(20min delay)
Last $6.77		Change 0.130(1.96%)		Mkt cap ! $4.894B

Open	High	Low	Value	Volume
$6.63	$6.77	$6.63	$10.00M	1.485M

FDA Approval, page-149

Ava Risk Group expands US presence with A$0.7M Substation Deal

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Microcap Wrap: 5 explorers with news out today

Recce's R327 found effective against E.coli during clinical trial

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Silver Mines models five new calderas close to 396Moz Bowdens deposit

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

FDA Approval, page-149

Top Stories

Ava Risk Group expands US presence with A$0.7M Substation Deal

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Microcap Wrap: 5 explorers with news out today

Recce's R327 found effective against E.coli during clinical trial

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Silver Mines models five new calderas close to 396Moz Bowdens deposit

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News